MetaCap

Aurinia Pharmaceuticals (AUPH) vs Biohaven (BHVN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biohaven (BHVN) has outperformed Aurinia Pharmaceuticals (AUPH) over the past year, gaining 27.9% versus a loss of 6.3%. Aurinia Pharmaceuticals is the larger company by market cap ($1.97 billion vs $1.87 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AUPH-6.25%BHVN+27.86%
+79%+29%-21%
Nov 21, 20251 yearNov 20, 2026
AUPH+109.10%BHVN+73.63%
+750%+337%-76%
Sep 19, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AUPH versus BHVN key metrics
MetricAUPHBHVN
Share price$14.70$12.39
Market cap$1.97B$1.87B
1-day change-1.28%-9.23%
YTD return-7.84%+9.74%
1-year return-6.25%+27.86%
5-year return-23.95%—
P/E ratio (TTM)6.45—
Forward P/E12.67—
EPS (TTM)$2.28$-3.77
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$283.06M—
Revenue growth (YoY)+20.38%—
Net income (latest FY)$287.20M$-738.82M
Gross margin88.46%—
Operating margin37.06%—
Net margin101.47%—
52-week high$19.25$18.24
52-week low$13.52$8.03
Distance from 52-week high-23.64%-32.07%
Analyst consensusbuybuy
Avg. price target upside+25.85%+102.82%
Average volume858.74K3.24M
Shares outstanding134.00M151.06M
Employees128274
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BHVN has outperformed AUPH by 34.1 percentage points over the past year.

About Aurinia Pharmaceuticals

AUPH stock →

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

About Biohaven

BHVN stock →

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees

AUPH vs BHVN FAQ

Which is bigger, Aurinia Pharmaceuticals or Biohaven?

Aurinia Pharmaceuticals (AUPH) is larger, with a market capitalization of $1.97B compared with $1.87B for Biohaven (BHVN).

Which stock has performed better over the past year, AUPH or BHVN?

BHVN returned +27.86% over the past 12 months, compared with -6.25% for AUPH (price return, excluding dividends). Past performance does not predict future results.

Are Aurinia Pharmaceuticals and Biohaven in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons